Article ID Journal Published Year Pages File Type
4001316 Urologic Oncology: Seminars and Original Investigations 2006 5 Pages PDF
Abstract
The present case reminds the urologist that small-cell neuroendocrine carcinoma may be a variant form of disease recurrence during androgen ablation in advanced prostate cancer. A strategic approach for this phenotype evaluating serum neuroendocrine markers, such as ProGRP, should be taken when serum prostate-specific antigen does not reflect the disease state. This approach would allow one to choose alternative therapies targeting neuroendocrine cells other than androgen ablation.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , ,